Investigation of Three Contraceptive Hormone Patches in Regard to Inhibition of Ovulation Following Application Over 3 Treatment Cycles in Healthy, Young Women.

PHASE2CompletedINTERVENTIONAL
Enrollment

173

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

July 31, 2011

Study Completion Date

August 31, 2011

Conditions
Contraception
Interventions
DRUG

Gestodene/EE Patch (BAY86-5016)

0.55 mg ethinyl estradiol (EE) + 2.1 mg gestodene (GSD) per patch; 3 treatment cycles; 21 days per treatment cycle, i.e. 3 x 7 days patch-wearing phase and a patch-free interval of 7 days

DRUG

Gestodene/EE Patch (BAY86-5016)

0.35 mg ethinyl estradiol (EE) + 0.67 mg gestodene (GSD) per patch; 3 treatment cycles; 21 days per treatment cycle, i.e. 3 x 7 days patch-wearing phase and a patch-free interval of 7 days

DRUG

Gestodene/EE Patch (BAY86-5016)

0.275 mg ethiny estradiol (EE) + 1.05 mg gestodene (GSD) per patch; 3 treatment cycles; 21 days per treatment cycle, i.e. 3 x 7 days patch-wearing phase and a patch-free interval of 7 days

Trial Locations (2)

10115

Berlin

9713 GZ

Groningen

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY